Provera 10 mg Норвегия - норвежский - Statens legemiddelverk

provera 10 mg

pfizer as - medroksyprogesteronacetat - tablett - 10 mg

Salazopyrin EN 500 mg Норвегия - норвежский - Statens legemiddelverk

salazopyrin en 500 mg

pfizer as - sulfasalazin - enterotablett - 500 mg

Synarela 200 mikrog/ dose Норвегия - норвежский - Statens legemiddelverk

synarela 200 mikrog/ dose

pfizer as - nafarelinacetat - nesespray, oppløsning - 200 mikrog/ dose

Synfase - Норвегия - норвежский - Statens legemiddelverk

synfase -

pfizer as - noretisteron / etinyløstradiol - tablett

TicoVac 2.4 mikrog/ sprøyte Норвегия - норвежский - Statens legemiddelverk

ticovac 2.4 mikrog/ sprøyte

pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2.4 mikrog/ sprøyte

TicoVac Junior 1.2 mikrog/ sprøyte Норвегия - норвежский - Statens legemiddelverk

ticovac junior 1.2 mikrog/ sprøyte

pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 1.2 mikrog/ sprøyte

Terra-Cortril 30 mg/ g / 10 mg/ g Норвегия - норвежский - Statens legemiddelverk

terra-cortril 30 mg/ g / 10 mg/ g

pfizer as - oksytetrasyklinhydroklorid / hydrokortison - salve - 30 mg/ g / 10 mg/ g

Terramycin-Polymyxin B 30 mg/ g / 10000 IE/ g Норвегия - норвежский - Statens legemiddelverk

terramycin-polymyxin b 30 mg/ g / 10000 ie/ g

pfizer as - oksytetrasyklinhydroklorid / polymyksin b sulfat - salve - 30 mg/ g / 10000 ie/ g

Zeldox 80 mg Норвегия - норвежский - Statens legemiddelverk

zeldox 80 mg

pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 80 mg

Lorviqua Европейский союз - норвежский - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.